once it hits the market, page-19

TDA's analysis looks roughly like mine.

If you simplify away the generic share of market, share of profits, etc. a rough guide is that Alchemia can conservatively expect to earn around 10% of total US Arixtra/fondaparinux sales.

That needs to be risk weighted. It's possible the Dr Reddy/Alchemia generic will fail to achieve approval at all, or be blocked by patent litigation by GSK. It's possible that there will be long delays before approval.